{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:31:05Z","timestamp":1782448265158,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T00:00:00Z","timestamp":1703289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T00:00:00Z","timestamp":1703289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s00259-023-06575-9","type":"journal-article","created":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T04:34:16Z","timestamp":1703306056000},"page":"1246-1260","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Theranostic role of 89Zr- and 177Lu-labeled aflibercept in breast cancer"],"prefix":"10.1007","volume":"51","author":[{"given":"Qi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenpeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lele","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuicui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8729-4547","authenticated-orcid":false,"given":"Lei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,23]]},"reference":[{"key":"6575_CR1","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1038\/s41467-018-06616-0","volume":"9","author":"JJ Pitt","year":"2018","unstructured":"Pitt JJ, Riester M, Zheng Y, Yoshimatsu TF, Sanni A, Oluwasola O, et al. Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. Nat Commun. 2018;9:4181. https:\/\/doi.org\/10.1038\/s41467-018-06616-0.","journal-title":"Nat Commun"},{"key":"6575_CR2","doi-asserted-by":"publisher","first-page":"152","DOI":"10.2174\/1871520616666160502122724","volume":"17","author":"S Nagini","year":"2017","unstructured":"Nagini S. Breast cancer: current molecular therapeutic targets and new players. Anticancer Agents Med Chem. 2017;17:152\u201363. https:\/\/doi.org\/10.2174\/1871520616666160502122724.","journal-title":"Anticancer Agents Med Chem"},{"key":"6575_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00404-015-3859-y","volume":"293","author":"P Kumar","year":"2016","unstructured":"Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet. 2016;293:247\u201369. https:\/\/doi.org\/10.1007\/s00404-015-3859-y.","journal-title":"Arch Gynecol Obstet"},{"key":"6575_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/14737140.2021.1840984","volume":"21","author":"J Sukumar","year":"2021","unstructured":"Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N. Triple-negative breast cancer: promising prognostic biomarkers currently in development. Expert Rev Anticancer Ther. 2021;21:135\u201348. https:\/\/doi.org\/10.1080\/14737140.2021.1840984.","journal-title":"Expert Rev Anticancer Ther"},{"key":"6575_CR5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s10456-018-9634-5","volume":"21","author":"R Gianni-Barrera","year":"2018","unstructured":"Gianni-Barrera R, Butschkau A, Uccelli A, Certelli A, Valente P, Bartolomeo M, et al. PDGF-BB regulates splitting angiogenesis in skeletal muscle by limiting VEGF-induced endothelial proliferation. Angiogenesis. 2018;21:883\u2013900. https:\/\/doi.org\/10.1007\/s10456-018-9634-5.","journal-title":"Angiogenesis"},{"key":"6575_CR6","doi-asserted-by":"publisher","unstructured":"Kim W, Park A, Jang HH, Kim SE, Park KS. Breast tumor cell-stimulated bone marrow-derived mesenchymal stem cells promote the sprouting capacity of endothelial cells by promoting VEGF expression, mediated in part through HIF-1\u03b1 increase. Cancers (Basel). 2022;14. https:\/\/doi.org\/10.3390\/cancers14194711.","DOI":"10.3390\/cancers14194711"},{"key":"6575_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/15384047.2017.1294288","volume":"18","author":"H Sun","year":"2017","unstructured":"Sun H, Zhang D, Yao Z, Lin X, Liu J, Gu Q, et al. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry. Cancer Biol Ther. 2017;18:205\u201313. https:\/\/doi.org\/10.1080\/15384047.2017.1294288.","journal-title":"Cancer Biol Ther"},{"key":"6575_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/14740338.2022.2008905","volume":"21","author":"DK Lau","year":"2022","unstructured":"Lau DK, Mencel J, Chau I. Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer. Expert Opin Drug Saf. 2022;21:589\u201397. https:\/\/doi.org\/10.1080\/14740338.2022.2008905.","journal-title":"Expert Opin Drug Saf"},{"issue":"Suppl 1","key":"6575_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/s0365-6691(15)30003-4","volume":"90","author":"JR Azanza Perea","year":"2015","unstructured":"Azanza Perea JR, S\u00e1daba B. Aflibercept. An approach to pharmacology. Arch Soc Esp Oftalmol. 2015;90(Suppl 1):6\u201310. https:\/\/doi.org\/10.1016\/s0365-6691(15)30003-4.","journal-title":"Arch Soc Esp Oftalmol."},{"key":"6575_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1167\/tvst.10.4.9","volume":"10","author":"T Eissing","year":"2021","unstructured":"Eissing T, Stewart MW, Qian CX, Rittenhouse KD. Durability of VEGF suppression with intravitreal aflibercept and brolucizumab: using pharmacokinetic modeling to understand clinical outcomes. Transl Vis Sci Technol. 2021;10:9. https:\/\/doi.org\/10.1167\/tvst.10.4.9.","journal-title":"Transl Vis Sci Technol"},{"key":"6575_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115535","volume":"257","author":"D Jiang","year":"2023","unstructured":"Jiang D, Xu T, Zhong L, Liang Q, Hu Y, Xiao W, et al. Research progress of VEGFR small molecule inhibitors in ocular neovascular diseases. Eur J Med Chem. 2023;257: 115535. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115535.","journal-title":"Eur J Med Chem"},{"key":"6575_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104034","volume":"188","author":"A Thakur","year":"2023","unstructured":"Thakur A, Chorawala MR, Patel RS. A systemic review and meta-analysis of Aflibercept plus FOLFIRI regimen as a second-line treatment for metastatic colorectal cancer: A PRISMA compliant pooled analysis of randomized controlled trials and single arm studies to assess efficacy and safety. Crit Rev Oncol Hematol. 2023;188: 104034. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104034.","journal-title":"Crit Rev Oncol Hematol"},{"key":"6575_CR13","doi-asserted-by":"publisher","first-page":"S347","DOI":"10.4103\/jcrt.jcrt_1104_21","volume":"18","author":"C Erol","year":"2022","unstructured":"Erol C, Sendur Mehmet AN, Bilgetekin I, Garbioglu DB, Hamdard J, Akbas S, et al. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group. J Cancer Res Ther. 2022;18:S347\u201353. https:\/\/doi.org\/10.4103\/jcrt.jcrt_1104_21.","journal-title":"J Cancer Res Ther"},{"key":"6575_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.939425","volume":"12","author":"H Nakatsumi","year":"2022","unstructured":"Nakatsumi H, Komatsu Y, Muranaka T, Yuki S, Kawamoto Y, Harada K, et al. Study protocol for HGCSG1801: a multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies. Front Oncol. 2022;12: 939425. https:\/\/doi.org\/10.3389\/fonc.2022.939425.","journal-title":"Front Oncol"},{"key":"6575_CR15","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s12094-022-03047-8","volume":"25","author":"MG Raga","year":"2023","unstructured":"Raga MG, P\u00e9rez IP, Veiga RC, Sosa MM, Aguilera MJS, Rodr\u00edguez PL, et al. Maintenance of angiogenesis inhibition with aflibercept after progression to bevacizumab in metastatic colorectal cancer: real life study in the Valencian community. Clin Transl Oncol. 2023;25:1455\u201362. https:\/\/doi.org\/10.1007\/s12094-022-03047-8.","journal-title":"Clin Transl Oncol"},{"key":"6575_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejcsup.2020.02.003","volume":"15","author":"Y Garc\u00eda Garc\u00eda","year":"2020","unstructured":"Garc\u00eda Garc\u00eda Y, Mar\u00edn Alcal\u00e1 M, Mart\u00ednez VC. Anti-angiogenic therapy for ovarian cancer. EJC Suppl. 2020;15:77\u201386. https:\/\/doi.org\/10.1016\/j.ejcsup.2020.02.003.","journal-title":"EJC Suppl"},{"key":"6575_CR17","doi-asserted-by":"publisher","unstructured":"Andersson Y, Fleten KG, Abrahamsen TW, Reed W, Davidson B, Flatmark K. Anti-angiogenic treatment in Pseudomyxoma peritonei-still a strong preclinical rationale. Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13112819.","DOI":"10.3390\/cancers13112819"},{"key":"6575_CR18","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/mpa.0000000000002099","volume":"51","author":"K Perez","year":"2022","unstructured":"Perez K, Kulke MH, Horick NK, Regan E, Graham C, Scheutz S, et al. A phase II study of ziv-aflibercept in patients with advanced extrapancreatic neuroendocrine tumors. Pancreas. 2022;51:763\u20138. https:\/\/doi.org\/10.1097\/mpa.0000000000002099.","journal-title":"Pancreas"},{"key":"6575_CR19","doi-asserted-by":"publisher","first-page":"2057269","DOI":"10.1080\/19420862.2022.2057269","volume":"14","author":"P Zhao","year":"2022","unstructured":"Zhao P, Anami Y, Gao P, Fan X, Li L, Tsuchikama K, et al. Enhanced anti-angiogenetic effect of transferrin receptor-mediated delivery of VEGF-trap in a glioblastoma mouse model. MAbs. 2022;14:2057269. https:\/\/doi.org\/10.1080\/19420862.2022.2057269.","journal-title":"MAbs"},{"key":"6575_CR20","doi-asserted-by":"publisher","first-page":"1154685","DOI":"10.3389\/fonc.2023.1154685","volume":"13","author":"H Shi","year":"2023","unstructured":"Shi H, Guo N, Zhao Z, Liu L, Ni T, Zhang J, et al. Comparison of the second-line treatments for patients with small cell lung cancer sensitive to previous platinum-based chemotherapy: a systematic review and Bayesian network analysis. Front Oncol. 2023;13:1154685. https:\/\/doi.org\/10.3389\/fonc.2023.1154685.","journal-title":"Front Oncol"},{"key":"6575_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.clcc.2020.05.007","volume":"19","author":"S Camera","year":"2020","unstructured":"Camera S, Deleporte A, Bregni G, Trevisi E, Pretta A, Telli TA, et al. Momentum: a phase I trial investigating 2 schedules of capecitabine with aflibercept in patients with gastrointestinal and breast cancer. Clin Colorectal Cancer. 2020;19:311-8.e1. https:\/\/doi.org\/10.1016\/j.clcc.2020.05.007.","journal-title":"Clin Colorectal Cancer"},{"key":"6575_CR22","doi-asserted-by":"publisher","first-page":"36694","DOI":"10.1038\/srep36694","volume":"6","author":"FT Wu","year":"2016","unstructured":"Wu FT, Paez-Ribes M, Xu P, Man S, Bogdanovic E, Thurston G, et al. Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer. Sci Rep. 2016;6:36694. https:\/\/doi.org\/10.1038\/srep36694.","journal-title":"Sci Rep"},{"key":"6575_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.clbc.2012.09.007","volume":"12","author":"K Sideras","year":"2012","unstructured":"Sideras K, Dueck AC, Hobday TJ, Rowland KM Jr, Allred JB, Northfelt DW, et al. North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and\/or a taxane. Clin Breast Cancer. 2012;12:387\u201391. https:\/\/doi.org\/10.1016\/j.clbc.2012.09.007.","journal-title":"Clin Breast Cancer"},{"key":"6575_CR24","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1007\/s00259-021-05593-9","volume":"49","author":"L Kang","year":"2022","unstructured":"Kang L, Li C, Yang Q, Sutherlin L, Wang L, Chen Z, et al. (64)Cu-labeled daratumumab F(ab\u2019)(2) fragment enables early visualization of CD38-positive lymphoma. Eur J Nucl Med Mol Imaging. 2022;49:1470\u201381. https:\/\/doi.org\/10.1007\/s00259-021-05593-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6575_CR25","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1007\/s00259-018-3941-3","volume":"45","author":"L Kang","year":"2018","unstructured":"Kang L, Jiang D, England CG, Barnhart TE, Yu B, Rosenkrans ZT, et al. ImmunoPET imaging of CD38 in murine lymphoma models using (89)Zr-labeled daratumumab. Eur J Nucl Med Mol Imaging. 2018;45:1372\u201381. https:\/\/doi.org\/10.1007\/s00259-018-3941-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6575_CR26","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2967\/jnumed.120.246595","volume":"62","author":"L Kang","year":"2021","unstructured":"Kang L, Li C, Rosenkrans ZT, Engle JW, Wang R, Jiang D, et al. Noninvasive evaluation of CD20 expression using (64)Cu-labeled F(ab\u2019)(2) fragments of obinutuzumab in lymphoma. J Nucl Med. 2021;62:372\u20138. https:\/\/doi.org\/10.2967\/jnumed.120.246595.","journal-title":"J Nucl Med"},{"key":"6575_CR27","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00259-022-05954-y","volume":"50","author":"C Li","year":"2022","unstructured":"Li C, Liu J, Yang X, Yang Q, Huang W, Zhang M, et al. Theranostic application of (64)Cu\/(177)Lu-labeled anti-Trop2 monoclonal antibody in pancreatic cancer tumor models. Eur J Nucl Med Mol Imaging. 2022;50:168\u201383. https:\/\/doi.org\/10.1007\/s00259-022-05954-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6575_CR28","doi-asserted-by":"publisher","first-page":"2001879","DOI":"10.1002\/advs.202001879","volume":"8","author":"L Kang","year":"2021","unstructured":"Kang L, Li C, Rosenkrans ZT, Huo N, Chen Z, Ehlerding EB, et al. CD38-targeted theranostics of lymphoma with (89)Zr\/(177)Lu-labeled daratumumab. Adv Sci (Weinh). 2021;8:2001879. https:\/\/doi.org\/10.1002\/advs.202001879.","journal-title":"Adv Sci (Weinh)"},{"key":"6575_CR29","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1021\/acs.bioconjchem.0c00649","volume":"32","author":"C Li","year":"2021","unstructured":"Li C, Kang L, Fan K, Ferreira CA, Becker KV, Huo N, et al. ImmunoPET of CD146 in orthotopic and metastatic breast cancer models. Bioconjug Chem. 2021;32:1306\u201314. https:\/\/doi.org\/10.1021\/acs.bioconjchem.0c00649.","journal-title":"Bioconjug Chem"},{"key":"6575_CR30","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1021\/acs.molpharmaceut.1c00939","volume":"19","author":"C Li","year":"2022","unstructured":"Li C, Yang Q, Chen Z, Qiu Y, Du Y, Wang R, et al. Noninvasive evaluation of multidrug resistance via imaging of ABCG2\/BCRP multidrug transporter in lung cancer xenograft models. Mol Pharm. 2022;19:3521\u20139. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00939.","journal-title":"Mol Pharm"},{"key":"6575_CR31","doi-asserted-by":"publisher","first-page":"20220041","DOI":"10.1002\/exp.20220041","volume":"3","author":"Y Du","year":"2023","unstructured":"Du Y, Huo Y, Yang Q, Han Z, Hou L, Cui B, et al. Ultrasmall iron-gallic acid coordination polymer nanodots with antioxidative neuroprotection for PET\/MR imaging-guided ischemia stroke therapy. Exploration (Beijing). 2023;3:20220041. https:\/\/doi.org\/10.1002\/exp.20220041.","journal-title":"Exploration (Beijing)"},{"key":"6575_CR32","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1038\/s41467-020-16199-4","volume":"11","author":"O Saatci","year":"2020","unstructured":"Saatci O, Kaymak A, Raza U, Ersan PG, Akbulut O, Banister CE, et al. Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer. Nat Commun. 2020;11:2416. https:\/\/doi.org\/10.1038\/s41467-020-16199-4.","journal-title":"Nat Commun"},{"key":"6575_CR33","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1021\/acs.molpharmaceut.8b00027","volume":"15","author":"R Yudistiro","year":"2018","unstructured":"Yudistiro R, Hanaoka H, Katsumata N, Yamaguchi A, Tsushima Y. Bevacizumab radioimmunotherapy (RIT) with accelerated blood clearance using the avidin chase. Mol Pharm. 2018;15:2165\u201373. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00027.","journal-title":"Mol Pharm"},{"key":"6575_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000499583","volume":"97","author":"B Mery","year":"2019","unstructured":"Mery B, Rowinski E, Vallard A, Jacquin JP, Simoens X, Magn\u00e9 N, et al. Advocacy for a new oncology research paradigm: the model of bevacizumab in triple-negative breast cancer in a French cohort study. Oncology. 2019;97:1\u20136. https:\/\/doi.org\/10.1159\/000499583.","journal-title":"Oncology"},{"key":"6575_CR35","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ajo.2021.01.027","volume":"227","author":"JF Korobelnik","year":"2021","unstructured":"Korobelnik JF, Larsen M, Eter N, Bailey C, Wolf S, Schmelter T, et al. Efficacy and safety of intravitreal aflibercept treat-and-extend for macular edema in central retinal vein occlusion: the CENTERA study. Am J Ophthalmol. 2021;227:106\u201315. https:\/\/doi.org\/10.1016\/j.ajo.2021.01.027.","journal-title":"Am J Ophthalmol"},{"key":"6575_CR36","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1097\/iae.0000000000003128","volume":"41","author":"P Mitchell","year":"2021","unstructured":"Mitchell P, Holz FG, Hykin P, Midena E, Souied E, Allmeier H, et al. Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: the ARIES study: a randomized clinical trial. Retina. 2021;41:1911\u201320. https:\/\/doi.org\/10.1097\/iae.0000000000003128.","journal-title":"Retina"},{"key":"6575_CR37","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa2204225","volume":"387","author":"CD Jhaveri","year":"2022","unstructured":"Jhaveri CD, Glassman AR, Ferris FL 3rd, Liu D, Maguire MG, Allen JB, et al. Aflibercept monotherapy or bevacizumab first for diabetic macular edema. N Engl J Med. 2022;387:692\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa2204225.","journal-title":"N Engl J Med"},{"key":"6575_CR38","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1001\/jama.2022.10564","volume":"328","author":"A Stahl","year":"2022","unstructured":"Stahl A, Sukgen EA, Wu WC, Lepore D, Nakanishi H, Mazela J, et al. Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity: the FIREFLEYE randomized clinical trial. JAMA. 2022;328:348\u201359. https:\/\/doi.org\/10.1001\/jama.2022.10564.","journal-title":"JAMA"},{"key":"6575_CR39","doi-asserted-by":"publisher","first-page":"323","DOI":"10.34172\/apb.2020.039","volume":"10","author":"S Malekian","year":"2020","unstructured":"Malekian S, Rahmati M, Sari S, Kazemimanesh M, Kheirbakhsh R, Muhammadnejad A, et al. Expression of diverse angiogenesis factor in different stages of the 4T1 tumor as a mouse model of triple-negative breast cancer. Adv Pharm Bull. 2020;10:323\u20138. https:\/\/doi.org\/10.34172\/apb.2020.039.","journal-title":"Adv Pharm Bull."},{"key":"6575_CR40","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s00259-002-1054-4","volume":"30","author":"WA Breeman","year":"2003","unstructured":"Breeman WA, van der Wansem K, Bernard BF, van Gameren A, Erion JL, Visser TJ, et al. The addition of DTPA to [177Lu-DOTA0, Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity. Eur J Nucl Med Mol Imaging. 2003;30:312\u20135. https:\/\/doi.org\/10.1007\/s00259-002-1054-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6575_CR41","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/s0969-8051(00)00196-7","volume":"28","author":"WP Li","year":"2001","unstructured":"Li WP, Ma DS, Higginbotham C, Hoffman T, Ketring AR, Cutler CS, et al. Development of an in vitro model for assessing the in vivo stability of lanthanide chelates. Nucl Med Biol. 2001;28:145\u201354. https:\/\/doi.org\/10.1016\/s0969-8051(00)00196-7.","journal-title":"Nucl Med Biol"},{"key":"6575_CR42","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/nrclinonc.2012.188","volume":"9","author":"RJ Hicks","year":"2012","unstructured":"Hicks RJ, Hofman MS. Is there still a role for SPECT-CT in oncology in the PET-CT era? Nat Rev Clin Oncol. 2012;9:712\u201320. https:\/\/doi.org\/10.1038\/nrclinonc.2012.188.","journal-title":"Nat Rev Clin Oncol"},{"key":"6575_CR43","first-page":"74","volume":"7","author":"A Sabet","year":"2017","unstructured":"Sabet A, Haug AR, Eiden C, Auernhammer CJ, Simon B, Bartenstein P, et al. Efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis. Am J Nucl Med Mol Imaging. 2017;7:74\u201383.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"6575_CR44","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1084\/jem.20052494","volume":"203","author":"EA Reits","year":"2006","unstructured":"Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203:1259\u201371. https:\/\/doi.org\/10.1084\/jem.20052494.","journal-title":"J Exp Med"},{"key":"6575_CR45","doi-asserted-by":"publisher","unstructured":"Hecht M, Eckstein M, Rutzner S, von der Gr\u00fcn J, Illmer T, Klautke G, et al. Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer. J Immunother Cancer. 2022;10. https:\/\/doi.org\/10.1136\/jitc-2021-003747.","DOI":"10.1136\/jitc-2021-003747"},{"key":"6575_CR46","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/nm.1864","volume":"14","author":"DX Fu","year":"2008","unstructured":"Fu DX, Tanhehco Y, Chen J, Foss CA, Fox JJ, Chong JM, et al. Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors. Nat Med. 2008;14:1118\u201322. https:\/\/doi.org\/10.1038\/nm.1864.","journal-title":"Nat Med"},{"key":"6575_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2016.08.016","volume":"512","author":"Y Sheng","year":"2016","unstructured":"Sheng Y, You Y, Chen Y. Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer. Int J Pharm. 2016;512:1\u201313. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.08.016.","journal-title":"Int J Pharm"},{"key":"6575_CR48","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10549-017-4169-9","volume":"163","author":"A Chakraborty","year":"2017","unstructured":"Chakraborty A, Hatzis C, DiGiovanna MP. Co-targeting the HER and IGF\/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease. Breast Cancer Res Treat. 2017;163:37\u201350. https:\/\/doi.org\/10.1007\/s10549-017-4169-9.","journal-title":"Breast Cancer Res Treat"},{"key":"6575_CR49","doi-asserted-by":"publisher","first-page":"2495958","DOI":"10.1155\/2021\/2495958","volume":"2021","author":"M Chen","year":"2021","unstructured":"Chen M, Lin Z, Yao G, Hong X, Xue X, Chen L. A novel NIR fluorescent nanoprobe targeting HER2-positive breast cancer: Tra-TTR-A. Bioinorg Chem Appl. 2021;2021:2495958. https:\/\/doi.org\/10.1155\/2021\/2495958.","journal-title":"Bioinorg Chem Appl"},{"key":"6575_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202204718","volume":"9","author":"P Sun","year":"2022","unstructured":"Sun P, Qu F, Zhang C, Cheng P, Li X, Shen Q, et al. NIR-II excitation phototheranostic platform for synergistic photothermal therapy\/chemotherapy\/chemodynamic therapy of breast cancer bone metastases. Adv Sci (Weinh). 2022;9: e2204718. https:\/\/doi.org\/10.1002\/advs.202204718.","journal-title":"Adv Sci (Weinh)"}],"updated-by":[{"DOI":"10.1007\/s00259-023-06590-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000}}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06575-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06575-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06575-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T11:06:26Z","timestamp":1711019186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06575-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,23]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["6575"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06575-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00259-023-06590-w","asserted-by":"object"}]},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,23]]},"assertion":[{"value":"26 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00259-023-06590-w","URL":"https:\/\/doi.org\/10.1007\/s00259-023-06590-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Animal Committee of Peking University First Hospital (No. 2022018).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The requirement for informed consent was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}